A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)

Demographic and Clinical Characteristics, Treatment Patterns, and Real-world Effectiveness of Lanadelumab in Patients With Hereditary Angioedema Type I or II in the United Kingdom: an Ambispective Cohort Study

The main aim of this study is to compare the HAE attacks (both total and those requiring on-demand treatment) in the 12 months before and up to 24 months after initiation of treatment with lanadelumab.

This study is conducted in the United Kingdom where participants were treated or about to be treated with landelumab according to their routine practice at hospitals. Data will be directly collected from participants via study diaries, questionnaires, their medical records, and study doctors treating them. Participants will be contacted every 3 months during study participation (via phone).

Inclusion:

• Documented diagnosis of HAE type I or II (confirmed through laboratory testing)
• Documented initiation of treatment with lanadelumab or due to be initiated within next 4 weeks
• Greater than or equal to (≥)12 years of age at initiation of treatment with lanadelumab
• ≥12 months of continuous medical record data before initiation of treatment with lanadelumab

Exclusion:

• Exposure to lanadelumab administered as an investigation product in a clinical trial setting at any point in time